Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan

Investigational New Drugs - Tập 38 Số 1 - Trang 172-180 - 2020
Sadahisa Ogasawara1,2, Yoshihiko Ooka1, Norio Itokawa3, Masatoshi Inoue4, Shinichiro Okabe5, Atsuyoshi Seki6, Yuki Haga7, Masamichi Obu8, Masanori Atsukawa9, Ei Itobayashi4, Hideaki Mizumoto6, Norío Sugiura7, Ryosaku Azemoto8, Kengo Kanayama1, Hiroaki Kanzaki1, Susumu Maruta1, Takahiro Maeda1, Yuko Kusakabe1, Masayuki Yokoyama1, Kazufumi Kobayashi1,2, Soichiro Kiyono1, Masato Nakamura1, Tomoko Saito1, Eiichiro Suzuki1, Shingo Nakamoto1, Shin Yasui1, Akinobu Tawada1,10, Tadatoshi Chiba1, Makoto Arai1,10, Tatsuo Kanda1,11, Hitoshi Maruyama1,12, Naoya Kato1,2
1Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan
2Translational Research and Development Center, Chiba University Hospital, Chiba, Japan
3Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan
4Department of Gastroenterology, Asahi General Hospital, Asahi, Japan
5Department of Gastroenterology, Matsudo City General Hospital, Matsudo, Japan
6Department of Gastroenterology, Funabashi Municipal Medical Center, Funabashi, Japan
7Department of Gastroenterology, National Hospital Organization Chiba Medical Center, Chiba, Japan
8Department of Gastroenterology, Kimitsu Chuo Hospital, Kisarazu, Japan
9Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
10Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan
11Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
12Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan

Tóm tắt

Từ khóa


Tài liệu tham khảo

Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34

Kudo M, Matsui O, Izumi N et al (2014) JSH consensus-based clinical practice guidelines for the Management of Hepatocellular Carcinoma: 2014 update by the liver Cancer study Group of Japan. Liver Cancer 3:458–468

Omata M, Cheng AL, Kokudo N et al (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11:317–370

European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236

Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358–380

Ogasawara S, Chiba T, Ooka Y et al (2014) Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology 87:330–341

Arizumi T, Ueshima K, Minami T et al (2015) Effectiveness of Sorafenib in patients with Transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma. Liver Cancer 4:253–262

Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109

Wilhelm SM, Dumas J, Adnane L et al (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245–255

Abou-Elkacem L, Arns S, Brix G et al (2013) Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 12:1322–1331

Johnson PJ, Qin S, Park JW et al (2013) Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31:3517–3524

Cainap C, Qin S, Huang WT et al (2015) Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 33:172–179

Llovet JM, Decaens T, Raoul JL et al (2013) Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 31:3509–3516

Zhu AX, Park JO, Ryoo BY et al (2015) Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 16:859–870

Zhu AX, Kudo M, Assenat E et al (2014) Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 312:57–67

Kudo M, Moriguchi M, Numata K et al (2017) S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. Lancet Gastroenterol Hepatol 2:407–417

Bruix J, Qin S, Merle P et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56–66

Nannini M, Nigro MC, Vincenzi B et al (2017) Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. Ther Adv Med Oncol 9:731–739

Yamaguchi K, Komatsu Y, Satoh T, et al (2019) Large-scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting. Oncologist

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163–1173

Ueshima K, Nishida N, Kudo M (2017) Sorafenib-Regorafenib sequential therapy in advanced hepatocellular carcinoma: a single-institute experience. Dig Dis 35:611–617

Finn RS, Merle P, Granito A et al (2018) Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial. J Hepatol 69:353–358

Yoo C, Park JW, Kim YJ, et al (2018) Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. Investig New Drugs

Hiraoka A, Kumada T, Kariyama K et al (2019) Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: multicenter analysis. Cancer Med 8:137–146

Abou-Alfa GK, Meyer T, Cheng AL et al (2018) Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 379:54–63

Zhu AX, Kang YK, Yen CJ et al (2019) Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:282–296

Ogasawara S, Chiba T, Ooka Y et al (2018) Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Investig New Drugs 36:332–339

Uchikawa S, Kawaoka T, Aikata H et al (2018) Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. Hepatol Res 48:814–820

Terashima T, Yamashita T, Sunagozaka H et al (2018) Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: prospects for regorafenib therapy. Hepatol Res 48:956–966

Thông tin
Thông tin xuất bản

Investigational New Drugs

Tập 38 Số 1

172-180

Thông tin tác giả